Restoring Life's Potential
with Innovative Treatments that Enable the Nervous System to Repair Itself
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
When there is damage to the nervous system a scar forms. The scar forms in response to acute damage, such as spinal cord injury (SCI), or in chronic diseases, such as multiple sclerosis (MS) and Alzheimer’s disease (AD). Scars contain molecules called chondroitin sulfate proteoglycans (CSPGs). CSPGs bind to a cellular receptor called protein tyrosine phosphatase sigma (PTPσ). This interaction of CSPGs and PTPσ initially helps to contain damage, but in the long term it interferes with repair of the nervous system.
NervGen’s lead drug candidate, NVG-291, relieves the inhibitory effects of CSPGs and thus enables nervous system repair. NVG-291 is a first-in-class experimental drug administered by injection under the skin. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.
NVG-291 is currently in a Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability, and metabolism.
After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
Our technology was developed in the laboratory of Dr. Jerry Silver, a renowned spinal cord injury and regenerative medicine researcher and Professor of Neurosciences at Case Western Reserve University (CWRU) in Cleveland, Ohio.
Dr. Silver’s research focuses on the glial scar which forms at sites of a physical injury such as spinal cord injury, as well as sites of inflammatory damage from neurodegenerative diseases.
Dr. Silver and his collaborators were able to discover a constituent in scars that is a major inhibitor of the body’s natural ability to regrow and regenerate, and the key neural receptor that binds to the constituent to inhibit nerve regeneration, known as protein tyrosine phosphatase sigma (PTPσ).
The NervGen Story
In this inspiring & heartfelt video, Dr. Jerry Silver, Professor of Neurosciences, Case Western Reserve University, shares his journey and how the research carried out in his lab led to the formation of NervGen.
The video highlights how NervGen is developing Dr. Silver’s foundational discoveries into a disruptive technology that is aimed at changing the paradigm of how nervous system damage will be treated.